Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | USP14 | P54578 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14876491 | 0.79 | HIF1A (0.36) | UCHL1USP14DGAT1F2F11 | |
| SCHEMBL1055540 | 0.74 | AAK1 (0.39) | DGAT1 | |
| SCHEMBL2157168 | 0.73 | LIPG (0.37) | UCHL1DGAT1F2F11PRSS1 | |
| SCHEMBL17442848 | 0.71 | CXCR2 (0.38) | UCHL1DGAT1 | |
| SCHEMBL9938876 | 0.69 | UCHL1 (0.33) | UCHL1 | |
| SCHEMBL28989475 | 0.69 | LIPG (0.52) | DGAT1F11 | |
| SCHEMBL29138191 | 0.68 | LPL (0.38) | DGAT1F11 | |
| SCHEMBL26101972 | 0.68 | UCHL1 (0.33) | UCHL1DGAT1F2F11PRSS1 | |
| SCHEMBL58552 | 0.68 | LIPE (0.33) | UCHL1DGAT1F2F11PRSS1 | |
| SCHEMBL30773539 | 0.67 | BACE1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466167-B2 | Compounds and compositions as TLR activity modulators | IRM LLC (BM) | 2013-06-18 | — | — | US | disclosed |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR5, TLR8, TLR7 | UCHL1 4870/4885USP14 3094/4885DGAT1 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.